Lotus Pharmaceuticals Announces Participation in PHARMCHINA's 64th National Drug Fair Conference

Dec 09, 2010, 06:55 ET from Lotus Pharmaceuticals, Inc.

BEIJING, Dec. 9, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it will participate in PHARMCHINA's 64th National Drug Fair Conference, to be held December 9-11, 2010 at the Nanchang International Exhibition Center in Nanchang, Jiangxi Province, PRC.

More than 100,000 visitors are expected to attend PHARMCHINA, the largest exhibition in the Chinese pharmaceutical industry. Lotus' operating entity, Liang Fang Pharmaceutical, Ltd., will exhibit its product offerings at Booth #203 during the event.

Chairman and Chief Executive Officer Mr. Zhongyi Liu stated, "PHARMCHINA provides us with a valuable opportunity to increase awareness of our self-branded and third-party distributed pharmaceutical products. At this event, we intend to seek new distribution channels and business partners to strengthen our national sales network and grow our market share. We will also seek out pharmaceutical products that we can begin distributing to our growing customer base, as well as innovative development-stage products for potential acquisition."

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.


At the Company:

Xing Shen, Ph.D.

VP of Corporate Development

Lotus Pharmaceuticals, Inc.

Tel: +1-415-690-7688

Email: shen@lotuspharma.com

Web: http://www.lotuspharma.com

Investor Relations:

Dave Gentry

RedChip Companies, Inc.

Tel: +1-800-733-2447, Ext. 104

Email: info@redchip.com

Web: http://www.redchip.com

SOURCE Lotus Pharmaceuticals, Inc.